Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05255601 · OUTCOME

Time to Maximum Concentration (Tmax)

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma · Source last updated 2026-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
hour
Interval / dispersion
Full Range
Time frame
Cycle 1 Day 1

What was measured

Time of maximum observed serum concentration of Analyte BMS-986016

Analysis population: PK Population

Groups in this outcome

Part A - Flat Dosing (AF)

Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W

Part A - Age/Weight-based Dosing (AW)

Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part A - Flat Dosing (AF)4
Part A - Age/Weight-based Dosing (AW)1

Reported measurements

Source class 1
Values in hour · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Part A - Flat Dosing (AF)0.74Not reported0.581.00Not reported
Part A - Age/Weight-based Dosing (AW)0.50Not reported0.500.50Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.58
        upper Limit
        1.00
        value
        0.74
      2. group Id
        OG001
        lower Limit
        0.50
        upper Limit
        0.50
        value
        0.50
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    2. group Id
      OG001
      value
      1
    units
    Participants
description
Time of maximum observed serum concentration of Analyte BMS-986016
dispersion Type
Full Range
groups
  1. description
    Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W
    id
    OG000
    title
    Part A - Flat Dosing (AF)
  2. description
    Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W
    id
    OG001
    title
    Part A - Age/Weight-based Dosing (AW)
param Type
MEDIAN
population Description
PK Population
reporting Status
POSTED
time Frame
Cycle 1 Day 1
title
Time to Maximum Concentration (Tmax)
type
PRIMARY
unit Of Measure
hour

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice